EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

New pharmacotherapy options for noninfectious posterior uveitis

Uwe Pleyer, Piergiorgio Neri, Christoph Deuter

International Ophthalmology · 2021-06 · 41 (6) · 2265-2281

DOI: 10.1007/s10792-021-01763-8 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Ophthalmology, online erschienen am 25.02.2021. Verfasst von Uwe Pleyer und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Charité - Universitätsmedizin, Berlin Institute of Health, 13353, Berlin, Germany. uwe.pleyer@charite.de. Hauptthemen laut MEDLINE: Antirheumatic Agents, Uveitis, Uveitis, Intermediate, Uveitis, Posterior. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 110 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Charité.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Noninfectious inflammation of the posterior eye segment represents an important cause of visual impairment. It often affects relatively young people and causes a significant personal and social impact. Although steroids and nonbiologic- Disease-Modifying Antirheumatic Drugs (nbDMARDs) are effective both in acute and long- lasting diseases, however they are increasingly being replaced by biologic (DMARDs). bDMARD. This article therefore aims to identify recent advances in the therapy of noninfectious posterior segment uveitis.

Methods

A Medline-search was conducted using the terms: nbDMARD, bDMARD, posterior uveitis, intermediate uveitis, treatment, corticosteroid. In addition, clinical studies were included as registered at ClinicalTrials.gov.

Results

Currently two major lines of treatments can be identified: (1) the intraocular application of anti-inflammatory agents and (2) the introduction of new agents, e.g., (bDMARDs) and small-molecule-inhibitors. Whereas intravitreal treatments have the advantage to avoid systemic side effects, new systemic agents are progressively earning credit on the basis of their therapeutic effects.

Conclusion

Even when current treatment strategies are still hampered by the limited number of randomized controlled trials, promising progress and continuous efforts are seen.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antirheumatic AgentsUveitisUveitis, IntermediateUveitis, PosteriorAdolescentAdrenal Cortex HormonesAnti-Inflammatory AgentsHumans

Stichwörter der Autor:innen

CorticosteroidTherapyUveitisbDMARDnbDMARDtsDMARD

Substanzen

Adrenal Cortex HormonesAnti-Inflammatory AgentsAntirheumatic Agents

Autor:innen und Institutionen

  • Department of Ophthalmology, Charité - Universitätsmedizin, Berlin Institute of Health, 13353, Berlin, Germany. uwe.pleyer@charite.de.
  • Cleveland Clinic Abu Dhabi, Abu Dhabi, UAE.
  • Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH, USA.
  • Centre for Ophthalmology, University Hospital, 72076, Tuebingen, Germany.

Förderung

  • Charité

Zitieren

APA

Pleyer, U., Neri, P., & Deuter, C. (2021). New pharmacotherapy options for noninfectious posterior uveitis. International Ophthalmology, 41(6), 2265-2281. https://doi.org/10.1007/s10792-021-01763-8

Vancouver

Pleyer U, Neri P, Deuter C. New pharmacotherapy options for noninfectious posterior uveitis. International Ophthalmology. 2021;41(6):2265-2281. doi:10.1007/s10792-021-01763-8

BibTeX
@article{Pleyer2021,
  author = {Pleyer, Uwe and Neri, Piergiorgio and Deuter, Christoph},
  title = {New pharmacotherapy options for noninfectious posterior uveitis},
  journal = {International Ophthalmology},
  year = {2021},
  volume = {41},
  number = {6},
  pages = {2265--2281},
  doi = {10.1007/s10792-021-01763-8}
}
Kostenlos starten →